Tag: Healthcare innovation
-
Weighing the Costs: Reimbursement of Anti-Obesity Medicines in the US and Europe
With the global burden of obesity continuing to rise, the tension between established reimbursement rules, increased efficacy of new anti-obesity medicines and the need to tackle this population health issue is becoming more pronounced. Reimbursement policies for anti-obesity medications vary significantly by region and are driven by country-specific healthcare priorities, reimbursement policies and budget constraints,…
-
Announcement of UK IDAP Pilot for medical devices – What does it mean for reimbursement?
The Innovative Devices Access Pathway (IDAP) Pilot is a first step to providing a faster and supported route to regulatory approval, access and adoption of innovative devices. But what precisely does this mean ultimately for access and reimbursement?